Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen

Celcuity (NASDAQ:CELC) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

Other equities research analysts also recently issued reports about the stock. Leerink Partners lifted their price target on shares of Celcuity from $28.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, July 28th. Guggenheim assumed coverage on Celcuity in a research note on Monday, September 22nd. They set a “buy” rating on the stock. Stifel Nicolaus initiated coverage on Celcuity in a research report on Tuesday, July 1st. They set a “buy” rating and a $30.00 target price for the company. HC Wainwright increased their target price on Celcuity from $66.00 to $77.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.50.

Celcuity Trading Up 9.2%

Shares of Celcuity stock opened at $77.51 on Friday. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The firm has a 50-day moving average of $54.18 and a 200-day moving average of $30.30. Celcuity has a 52-week low of $7.57 and a 52-week high of $83.00. The stock has a market cap of $3.29 billion, a PE ratio of -22.47 and a beta of 0.70.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14). As a group, sell-side analysts forecast that Celcuity will post -2.62 EPS for the current year.

Hedge Funds Weigh In On Celcuity

A number of institutional investors have recently modified their holdings of the business. Baker BROS. Advisors LP increased its holdings in shares of Celcuity by 59.0% during the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock worth $43,046,000 after buying an additional 1,579,182 shares in the last quarter. Soleus Capital Management L.P. grew its position in Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Celcuity in the 2nd quarter worth about $3,197,000. Ameriprise Financial Inc. raised its position in Celcuity by 27.6% in the second quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock valued at $10,263,000 after purchasing an additional 166,324 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its stake in shares of Celcuity by 9.8% during the second quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after purchasing an additional 123,774 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.